Tim Anderson
Stock Analyst at Bank of America Securities
(4.56)
# 972
Out of 4,579 analysts
264
Total ratings
63.2%
Success rate
15.9%
Average return
Main Sectors:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $16 → $15 | $19.49 | -23.04% | 3 | Dec 18, 2025 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $43 → $46 | $27.21 | +69.06% | 8 | Dec 18, 2025 | |
| APGE Apogee Therapeutics | Reiterated: Buy | $82 → $81 | $134.28 | -39.68% | 8 | Dec 18, 2025 | |
| AARD Aardvark Therapeutics | Reiterated: Buy | $25 | $6.69 | +273.69% | 7 | Dec 18, 2025 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $950 → $1,286 | $1,197.53 | +7.39% | 36 | Dec 1, 2025 | |
| MRK Merck & Co. | Reiterated: Buy | $98 → $105 | $130.76 | -19.70% | 29 | Nov 17, 2025 | |
| MRNA Moderna | Reiterated: Sell | $24 → $21 | $55.63 | -62.25% | 10 | Nov 10, 2025 | |
| AMGN Amgen | Reiterated: Sell | $272 | $376.26 | -27.71% | 15 | Nov 5, 2025 | |
| BIIB Biogen | Reiterated: Hold | $167 | $200.14 | -16.56% | 12 | Nov 3, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $50 → $52 | $62.56 | -16.88% | 18 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $251 → $248 | $256.91 | -3.47% | 21 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $543 → $627 | $667.17 | -6.02% | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $28 → $30 | $24.67 | +21.61% | 34 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $130.52 | +7.26% | 17 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $198 → $204 | $265.95 | -23.29% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 11,500p | 12,888p | n/a | 1 | Feb 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $54.78 | n/a | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €102.00 → €105.00 | €77.79 | n/a | 2 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $156.11 | n/a | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | CHF 84.00 → CHF 88.00 | CHF 128.52 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 410.00 → CHF 430.00 | CHF 360.10 | n/a | 2 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $92 | $47.89 | n/a | 4 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $45 | $44.00 | n/a | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 107,029p | 1,961p | n/a | 1 | Feb 7, 2018 |
Amylyx Pharmaceuticals
Dec 18, 2025
Reiterated: Buy
Price Target: $16 → $15
Current: $19.49
Upside: -23.04%
Mineralys Therapeutics
Dec 18, 2025
Reiterated: Buy
Price Target: $43 → $46
Current: $27.21
Upside: +69.06%
Apogee Therapeutics
Dec 18, 2025
Reiterated: Buy
Price Target: $82 → $81
Current: $134.28
Upside: -39.68%
Aardvark Therapeutics
Dec 18, 2025
Reiterated: Buy
Price Target: $25
Current: $6.69
Upside: +273.69%
Eli Lilly and Company
Dec 1, 2025
Reiterated: Buy
Price Target: $950 → $1,286
Current: $1,197.53
Upside: +7.39%
Merck & Co.
Nov 17, 2025
Reiterated: Buy
Price Target: $98 → $105
Current: $130.76
Upside: -19.70%
Moderna
Nov 10, 2025
Reiterated: Sell
Price Target: $24 → $21
Current: $55.63
Upside: -62.25%
Amgen
Nov 5, 2025
Reiterated: Sell
Price Target: $272
Current: $376.26
Upside: -27.71%
Biogen
Nov 3, 2025
Reiterated: Hold
Price Target: $167
Current: $200.14
Upside: -16.56%
Bristol-Myers Squibb Company
Nov 3, 2025
Reiterated: Hold
Price Target: $50 → $52
Current: $62.56
Upside: -16.88%
Nov 3, 2025
Reiterated: Hold
Price Target: $251 → $248
Current: $256.91
Upside: -3.47%
Oct 29, 2025
Reiterated: Sell
Price Target: $543 → $627
Current: $667.17
Upside: -6.02%
Oct 22, 2025
Reiterated: Hold
Price Target: $28 → $30
Current: $24.67
Upside: +21.61%
Oct 17, 2025
Reiterated: Buy
Price Target: $140
Current: $130.52
Upside: +7.26%
Oct 15, 2025
Reiterated: Hold
Price Target: $198 → $204
Current: $265.95
Upside: -23.29%
Feb 19, 2024
Maintained: Buy
Price Target: 11,500p
Current: 12,888p
Upside: n/a
Jan 3, 2024
Downgraded: Hold
Price Target: n/a
Current: $54.78
Upside: n/a
Jan 3, 2024
Upgraded: Buy
Price Target: €102.00 → €105.00
Current: €77.79
Upside: n/a
May 9, 2022
Downgraded: Hold
Price Target: n/a
Current: $156.11
Upside: n/a
May 9, 2022
Downgraded: Hold
Price Target: CHF 84.00 → CHF 88.00
Current: CHF 128.52
Upside: n/a
Dec 29, 2021
Maintained: Buy
Price Target: CHF 410.00 → CHF 430.00
Current: CHF 360.10
Upside: n/a
Nov 1, 2021
Maintained: Buy
Price Target: $80 → $92
Current: $47.89
Upside: n/a
Feb 8, 2018
Reiterated: Hold
Price Target: $45
Current: $44.00
Upside: n/a
Feb 7, 2018
Maintained: Hold
Price Target: 107,029p
Current: 1,961p
Upside: n/a